Description
A prodrug form of remogliflozin A; inhibits human SGLT2 and SGLT1 (Kis = 1.95 and 43.1 μM, respectively); inhibits increases in plasma glucose levels in a glucose tolerance test in a rat model of STZ-induced diabetes at 3 and 10 mg/ml; increases fasting plasma insulin levels and reduces fasting plasma glucose and triglyceride levels, as well as urinary glucose excretion, in a db/db mouse model of diabetes with hyperinsulinemia and obesity at 10 and 30 mg/kg twice per day for 6 weeks
Formal name: 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, β-D-glucopyranoside 6-(ethyl carbonate)
Synonyms: GSK189075
Molecular weight: 522.6
CAS: 442201-24-3
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Transporter & Exchanger Modulators||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity